- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ultralow-dose "quadpill", a new strategy for BP lowering?
![Ultralow-dose quadpill, a new strategy for BP lowering? Ultralow-dose quadpill, a new strategy for BP lowering?](https://medicaldialogues.in/h-upload/2022/11/09/750x450_190373-antihypertensives.webp)
USA: Findings from the QUARTET USA trial have shown a potential use of a low-dose antihypertensive polypill for hypertension patients with no safety risk.
In the study assessing the safety and efficacy of a polypill containing quarter doses of four antihypertensive medications for hypertension versus an angiotensin receptor blocker (ARB) monotherapy, the researchers found that the polypill was not superior to the full-dose ARB monotherapy for improving BP control in patients with mild to moderate hypertension.
The study findings were presented at the 2022 Scientific Sessions of the American Heart Association (AHA) by Mark D. Huffman.
The authors hypothesized an ultra-low-dose quadruple-combination therapy (LDQT, including amlodipine 1.25 mg, candesartan 2 mg, bisoprolol 2.5 mg and indapamide 0.625 mg) would reduce office BP more effectively than initiating patients with standard dose monotherapy (candesartan 8 mg) following current clinical practice guidelines recommendations.
The researchers conducted a controlled, randomized, parallel-group trial over 12 weeks in Chicago, Illinois. Eligible patients were randomized in a ratio of 1:1 to receive either a polypill (n = 32) or candesartan 8 mg (n = 30). Patients in the ARB group also received a daily 5 mg dose of amlodipine if their BP was above goal.
The study included adults with increased BP (SBP>130 mmHg or DBP>80 mmHg) without cardiovascular disease.
The study demonstrated the following findings:
- The primary outcome, mean change in automated systolic BP, for polypill vs monotherapy, was: -4.8 mm Hg. Effects on 24-hour ambulatory blood pressure were similar.
- At 12 weeks, adjusted mean change in diastolic BP at 12 weeks: -4.9 mm Hg.
- A short-term (4-week) crossover trial of 18 participants suggests that LDQT lowers office blood pressure by 22/13 mmHg on average compared with placebo, with no difference in serious adverse events.
The trial's findings suggest that a treatment strategy of ultra-low dosing four BP-lowering medications did not result in a statistically more significant BP reduction compared to standard-dose ARB monotherapy for patients with mild to moderate hypertension.
The authors observed adverse events as more common in the intervention arm, but higher discontinuation rates were seen in the control arm. The enrollment target was not achieved due to COVID-19, and this limited sample size led to low power.
The findings were harmonious with the international QUARTET trial and indicate a potential use of a low-dose antihypertensive polypill for hypertension patients. The following steps will be the evaluation of a hypertensive polypill for assessing clinical outcomes.
Reference:
Presented by Dr Mark D. Huffman at the American Heart Association Scientific Sessions, Chicago, IL, November 6, 2022.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751